Table 1. Description of the studies included. (Continue...).

Study/country	Participants (N)	Type/identifier	Context	Eligibility criterion	Group	Outcome	Follow-up period
Abella et al. 8 United States of America	132	Parallel RCT NCT04329923	Post-exposure prophylaxis	Health care workers at COVID-19 units and no previous SARS-CoV-2 infection within the last 2 weeks	Placebo vs. Hydroxychloroquine, 600 mg/day for 8 weeks	- Positive test for SARS-CoV-2 during 8 weeks - Adverse events	8 weeks
Mitjà et al. 10 Spain	2,485	Cluster RCT NCT04304053	Post-exposure prophylaxis	Health care workers, household contacts, and nursing home workers or residents with no previous SARS-CoV-2 infection within the last 2 weeks	Usual care vs. Hydroxychloroquine, 800 mg on day 1, followed by 600 mg/day for 6 days	- Symptoms and positive test for SARS-CoV-2 - Hospitalization - Adverse events - Death	4 weeks
Boulware et al. 12 Unites States of America and Canada	821	Parallel RCT NCT04308668	Post-exposure prophylaxis	Household or occupational exposure to individuals with confirmed COVID-19 (distance ≤ 6 ft for >10 min with an infected subject or no use of face mask or eye shield)	Placebo vs. Hydroxychloroquine, 800 mg on day 1 and 600 mg within 6-8 h after the first dose, followed by 600 mg/day for 4 days	- Positive test for SARS-CoV-2 - Hospitalization - Adverse events - Deaths	2 weeks
Rajasingham et al. 11 United States of America and Canada	1,483	Parallel RCT NCT04328467	Pre-exposure prophylaxis	Health care workers with high risk for SARS-CoV-2 exposure (ICU, ER, COVID-19 units)	Placebo (folic acid) vs. Hydroxychloroquine, 400 mg on day 1 and 400 mg 6-8 h later, followed by 400 mg once a week for 12 weeks vs. Hydroxychloroquine, 400 mg on day 1 and 400 mg 6-8 h later, followed by 400 mg twice a week for 12 weeks	- COVID-19 free (no symptoms or negative RT-PCR result) - Hospitalization - Adverse events - Death	12 weeks
Barnabas et al. 9 United States of America	689	Parallel RCT NCT04328961	Post-exposure prophylaxis	Contact with an index case diagnosed SARS-CoV-2 infection within 96 h	Placebo vs. Hydroxychloroquine, 400 mg for 3 days, followed by 200 mg/day for 11 days	- Positive test for SARS-CoV-2 - Adverse events	14 days
Omrani et al. 14 Qatar	456	Triple parallel RCT NCT04349592	Outpatients with mild COVID-19	Mild disease or no symptoms, outpatients	Placebo vs. Hydroxychloroquine, 600 mg/day for 1 week vs. Hydroxychloroquine, 600 mg/day for 1 week + azithromycin	- Viral load - Hospitalization - Severe adverse events - Death	14 days
Reis et al. 13 Brazil	685	Triple parallel RCT NCT04403100	Mild COVID-19	Outpatients reporting less than 8 days since onset of flu-like symptoms or chest CT consistent with COVID-19	Placebo vs. Hydroxychloroquine, 800 mg as a loading dose, followed by 400 mg daily for 9 days vs. Lopinavir-ritonavir loading dose of 800 mg and 200 mg, respectively, every 12 h, followed by 400 mg and 100 mg, respectively, every 12 h for the following 9 days	- Adverse events - Severe adverse events - Hospitalization - Deaths	90 days
Mitjà et al. 15 Spain	293	Parallel RCT NCT04304053	Mild symptoms of COVID-19	Outpatients; symptoms for less than 5 days prior to enrollment	Usual care vs. Hydroxychloroquine, 800 mg on day 1, followed by 400 mg/day for 6 days	- Viral load - WHO progression scale - Hospitalization - Severe adverse events - Deaths	28 days
Skipper et al. 16 United States of America and Canada	491	Parallel RCT NCT04308668	Mild COVID-19	Outpatients, positive SARS-CoV-2 test and symptoms for ≤ 4 days or compatible symptoms after high-risk exposure to a contact with PCR-confirmed SARS-CoV-2 within the last 14 days	Placebo vs. Hydroxychloroquine, 800 mg once and 600 mg in 6-8 h, followed by 600 mg daily for another 4 more days	- Hospitalization - Adverse events - Deaths	14 days

RCT: randomized controlled trial.